Vaxxas is commercializing novel technology that dramatically enhances the performance of existing and next-generation vaccines. The company believes its innovative needle-free technology will help the world in rethinking what's possible with vaccines.
2025 - what a year 🎆This year we’ve made great progress towards our mission of creating a healthier world through patient-focused innovation with our needle-free vaccination technology for self-administration. Here’s a look back at the year as told by Vaxxas’ Senior Vice President, CMC Development Deborah Pascoe, PhD.Thank you to the #Vaxxas team, partners and investors. Through your support and dedication, we’re developing a technology for real-world impact. #2025highlights #biotechinnovation ...
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.